Brief: Elicera Gives Update On Carma Study

Elicera Therapeutics AB

22/05/2025 08:35

May 22 (Reuters) - Elicera Therapeutics AB ELIC.ST:

IN CARMA STUDY ELC-301 HAS SUCCESSFULLY CLEARED ALL ACTIVE LYMPHOMA IN TWO OUT OF THREE TREATED PATIENTS

ON CARMA STUDY: COHORT 2 HAS ALREADY BEEN INITIATED

Source text: ID:nWkr9PV2vM

Further company coverage: ELIC.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))